Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.
Nat Cancer · 2026-Jan · PMID 41507539
EFS
Fig. 4. EFS from definitive surgery in patients with stage III N2 or non-N2 NSCLC by pCR status. a – d , EFS from surgery in patients with N2 NSCLC by pCR status ( a ), patients with non-N2 NSCLC by pCR status ( b ), patients with N2 NSCLC without pCR who received at least one dose of adjuvant treatment ( c ) and patients with non-N2 NSCLC without pCR who received at least one dose of adjuvant treatment ( d ). The superscript letter ‘a’ indicates that EFS from surgery included only patients with definitive surgery and with pCR status available. The ‘Without pCR’ subgroup included patients with pCR negatively assessed. The superscript letter ‘b’ indicates that HRs were not calculated for subgroups with less than ten responders in either treatment arm. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate; NC, not calculated. Source data
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 4 | 2026-07-23T16:58:19+00:00 |